Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04390399 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date changed from estimate of Oct 31, 2025 to Oct 13, 2025 Completion date: Oct 31, 2025 to May 31, 2026v25 Show 1 more changeShow less
    • Completion date: Oct 31, 2025 to May 31, 2026
  2. 2 versions Re-verified since May 14, 2025, no change to tracked fieldsv23-v24
  3. Primary and study completion dates: Oct 31, 2024 to Oct 31, 2025v22
  4. Primary completion date: Jun 30, 2024 to Oct 31, 2024 Completion date: Sep 30, 2024 to Oct 31, 2024v21 Show 1 more changeShow less
    • Completion date: Sep 30, 2024 to Oct 31, 2024
  5. Trial status: Recruiting to Active, Not Recruiting Site details revised at 4 of 4 sitesv20 Show 1 more changeShow less
    • Site details revised at 4 of 4 sites
Show 18 earlier versionsHide 18 earlier versions
  1. Eligibility criteria expanded, about 30 words Study title shortened, about 3 wordsv19 Show 1 more changeShow less
    • Study title shortened, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  2. Site contacts updated at 1 of 4 sitesv18
  3. Re-verified, no change to tracked fieldsv17
  4. Site details revised at 1 of 4 sitesv16
  5. Study sites: 3 to 4v15
  6. Re-verified, no change to tracked fieldsv14
  7. Primary endpoint revised Enrollment target: 248 to 328 · Secondary endpoints revised (3)v13 Show 2 more changesShow less
    • Enrollment target: 248 to 328
    • Secondary endpoints revised (3)

    See this version in full on ClinicalTrials.gov ↗

  8. Primary completion date: Jun 30, 2021 to Jun 30, 2024 Completion date: Jun 30, 2022 to Sep 30, 2024v12 Show 1 more changeShow less
    • Completion date: Jun 30, 2022 to Sep 30, 2024
  9. Site contacts updated at 1 of 3 sites Eligibility criteria expanded, about 5 wordsv11 Show 1 more changeShow less
    • Eligibility criteria expanded, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  10. Re-verified, no change to tracked fieldsv10
  11. Site contacts updated at 1 of 3 sitesv9
  12. Eligibility criteria shortened, about 41 wordsv8 See this version in full on ClinicalTrials.gov ↗
  13. Study sites: 2 to 3 Eligibility criteria shortened, about 21 wordsv7 Show 1 more changeShow less
    • Eligibility criteria shortened, about 21 words

    See this version in full on ClinicalTrials.gov ↗

  14. Enrollment target: 268 to 248 Study sites: 1 to 2v6 Show 1 more changeShow less
    • Study sites: 1 to 2
  15. Start date changed from estimate of Jun 20, 2020 to Jul 21, 2020 Site contact updatedv5 Show 1 more changeShow less
    • Site contact updated
  16. Trial status: Not Yet Recruiting to Recruiting Primary completion date: May 11, 2023 to Jun 30, 2021 · Study sites: 0 to 1 · Completion date: May 11, 2023 to Jun 30, 2022 · 1 morev4 Show 4 more changesShow less
    • Primary completion date: May 11, 2023 to Jun 30, 2021
    • Study sites: 0 to 1
    • Completion date: May 11, 2023 to Jun 30, 2022
    • Start date: Jun 1, 2020 to Jun 20, 2020
  17. Start date: May 11, 2020 to Jun 1, 2020v3
  18. Secondary endpoints revised (3)v2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase 2, three-cohort (2 randomized and 1 single-arm), open-label study to evaluate the comparative efficacy and overall safety of standard-of-care chemotherapy versus standard-of-care chemotherapy in combination with aldoxorubicin HCl, N-803, and PD-L1 t-haNK in subjects with locally advanced or metastatic pancreatic cancer. Each treatment setting (ie, first line maintenance, second line, or third line or greater) will be evaluated independently as a separate cohort.
Trial Details
NCT Number NCT04390399
Lead Sponsor ImmunityBio, Inc.
Conditions Pancreatic Cancer
Enrollment 328 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov